On April 5, 2023 Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, reported that the company and its collaborators will present a total of 10 studies at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting from April 14-19 in Orlando, Florida (Press release, Foundation Medicine, APR 5, 2023, View Source [SID1234629852]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation highlights:
Over the past several years, there has been great progress in the ability to identify shed pieces of tumor, called circulating tumor DNA (ctDNA), within a cancer patient’s blood. In partnership with South Australian Immunogenomics Cancer Institute, Saint Bartholomew’s Hospital and Genentech, Foundation Medicine researchers used its novel methylation sequencing research platform to detect ctDNA as a prognostic biomarker in overall survival for patients with metastatic castrate resistant prostate cancer (mCRPC). Results from ctDNA evaluation as early as 6 weeks post treatment initiation were comparable to prostate specific antigen (PSA) response in second line mCRPC, providing an early non-invasive readout that is independent of PSA for monitoring therapy response in late stage mCRPC.
Historical barriers in the study of small cell lung cancer (SCLC) include the relative lack of human tumors studied, limited real-world data, and the lack of access to longitudinal samples to understand tumor evolution. In partnership with Stanford University and Vanderbilt University Medical Center, Foundation Medicine researchers conducted what is believed to be the largest SCLC study known to date to provide an improved understanding of genetic subtypes in SCLC, including patient ancestry and biopsy site-specific patterns, and better inform mechanisms of transformation to SCLC from non-small cell lung cancer that may further guide the development of personalized therapies for subsets of patients with this fatal tumor.
"Our experience sequencing over one million patient samples has allowed us to continuously improve our approach and have high confidence in the genomic abnormalities we detect and the results we deliver," said Priti Hegde, PhD, chief scientific officer at Foundation Medicine. "We are committed to bringing high-quality, differentiated and sustainable solutions, like options for sensitive ctDNA monitoring, to our physician and researcher partners so that they can provide all patients with the best treatment options for their unique cancers."
The following is a list of abstracts that will be presented at the meeting. To access all abstracts being presented at AACR (Free AACR Whitepaper), please visit AACR (Free AACR Whitepaper).org.
Follow Foundation Medicine on Twitter and LinkedIn for more updates from #AACR23 and visit us in person at Booth #3053.
Abstract #
Title
Collaborator
Product
Posters
305
Sunday, April 16
1:30 – 5:00 PM
POLE variant detection and classification is critical for identifying patients who may benefit from immunotherapy
FoundationOneCDx and FoundationOneLiquid CDx
228
Sunday, April 16
1:30 – 5:00 PM
Recurrent mitochondrial mutations in thyroid cancer
FoundationOneCDx
931
Sunday, April 16
1:30 – 5:00 PM
Comprehensive analysis of 3,600 small cell lung cancer cases reveals rare genetic subtypes and multiple mechanisms of histological transformation
Stanford University & Vanderbilt University Medical Center
FoundationOneCDx,
Foundation Medicine & Flatiron Health’s Joint Clinico-Genomic Database
933
Sunday, April 16
1:30 – 5:00 PM
The landscape of treatment patterns in non-small cell lung cancer post EGFR TKI treatment described by real world data from 428 patients
Flatiron Health, One Oncology
Foundation Medicine & Flatiron Health’s Joint Clinico-Genomic Database
938
Sunday, April 16
1:30 – 5:00 PM
Outcomes of Molecular Tumor Board recommendations for cancer patients with progression on standard of care therapies in Saudi Arabia
King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center
FoundationOneCDx
966
Sunday, April 16
1:30 – 5:00 PM
Exploration of a novel HRD signature (HRDsig) as a biomarker for rucaparib benefit in ARIEL2
Clovis Oncology, Imperial College London
FoundationOneCDx
305
Monday, April 17
9:00 a.m. – 12:30 p.m.
Co-occurrence of alterations impacting telomere elongation
FoundationOneCDx
2289
Monday, April 17
9:00 a.m. – 12:30 p.m.
Predicting tumor somatic vs versus clonal hematopoiesis (CH) origin for short variants (SV) with FoundationOneLiquid CDx assay
FoundationOneLiquid CDx
3362
Monday, April 17
1:30 – 5:00 p.m.
Evaluation of circulating tumor DNA kinetics as a prognostic biomarker for overall survival in metastatic castrate resistant prostate cancer using a novel methylation sequencing research assay
South Australian Immunogenomics Cancer Institute, Genentech, St. Bartholomew’s Hospital
Research methylation assay
3395
Monday, April 17
1:30 – 5:00 p.m.
Clinical Impact of FGFR inhibitors on FGFR2 Fusion Positive Pancreatic Cancer
Ohio State University
FoundationOneCDx